Strategic Patent Acquisition of Patent Assertion Entities and Defensive Patent Aggregators

Patent Assertion Entities and Antitrust: Operating Company Patent Transfers

Patent Assertion Entities and Antitrust: Operating Company Patent Transfers The Antitrust Source, April 2013. © 2013 by the American Bar Association. Reproduced with permission. All rights reserved. This information or any portion thereof may not be copied or disseminated in any form or by any means or stored in an electronic database or retrieval system without the express written consent of t...

Patent Assertion and U.s. Innovation

Strategic Patent Acquisitions

In recent years, we have seen a dramatic upsurge of “strategic patent acquisitions.” We define this as the acquisition of a portfolio of patents reading on a specified area such as flash memory, biosensors, database management, or wireless digital messaging, which may be asserted against “target products” in that area. In this article, we examine the economic effects of strategic patent acquisi...

Intravenous Paracetamol and Patent Ductus Arteriosus Closure

Background: Standard medical treatments for patent ductus arteriosus (PDA) closure are, including indomethacin/ibuprofen and surgical ligation. Nowadays, a new strategy to close PDA is the use of paracetamol. The present study aimed to describe the use of intravenous (IV) paracetamol for PDA closure in neonates who present a contraindication to ibuprofen or ibuprofen failure with no possibility...

Strategic Debt and Patent Races*

Most traditional studies of R&D do not consider that the use of leverage to finance R&D may affect total R&D expenditures in a patent race. We show that debt acts as a commitment to a smaller amount of total R&D spending (debt+equity) than would occur if firms were entirely equity financed. A commitment to lower R&D expenditure can be strategically beneficial; under a flow-cost model, debt indu...